BioSpace News Archive

CABOMETYX™ is the first and only single agent to demonstrate statistically significant clinical benefits across three key efficacy endpoints of overall survival (OS), progression free survival (PFS) and objective response rate (ORR) in a phase 3 study in previously treated patients with advanced renal cell cancer

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (FRA: 0K9) announced today that its subordinate voting shares have been upgraded to a listing on the OTCQB (“OTCQB”) Venture Market, trading under the ticker symbol “FSDDF.”

Jennewein Biotechnologie GmbH announces the introduction of a total biosynthesis approach for the production of human milk oligosaccharides (HMOs).

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy.

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has completed the planned enrollment of 380 patients in the global Toca 5 pivotal Phase 3 trial approximately three months ahead of schedule.

Silverback Therapeutics, Inc., a biotechnology company developing a pipeline of systemically delivered, locally active therapies, has closed an extension of its Series A financing to bring the total raised in the round to $47.5 million.

Today, Bright Health announced plans to expand upon its Medicare Advantage product offerings with the addition of individual health plans in both Maricopa and Pima counties.

To adapt to rapidly changing industry demands while providing the best possible access to patient care, healthcare organizations are selecting Oracle Cloud Applications.

The Arizona Bioindustry Association (AZBio) today announced that Clara Curiel-Lewandrowski, MD, of the University of Arizona Cancer Center is the 2018 Arizona Bioscience Researcher of the Year.

Respiratory Motion, Inc. is announcing the award of a group purchasing agreement as a Breakthrough Technology with Premier Inc., a leading healthcare improvement company.